NOTE: This activity is available only as part of a paid subscription series; it is not available for purchase as a single, stand-alone activity.
The goal of this program is to improve the management of immunocompromised patients during the COVID-19 pan-demic and the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for the management of peripheral artery disease. After hearing and assimilating this program, the clinician will be better able to:
1. Identify risk factors for poor outcomes from COVID infection in immunocompromised individuals.
2. Recognize the influence of immunosuppressive medication on outcomes and management of COVID.
3. Evaluate the effect of vaccination and prophylactic therapy for COVID infection in immunocompromised individuals.
4. Examine the mechanism of action, indications, and clinical outcomes of PCSK9 inhibitors for the management of peripheral arterial disease.
5. Review recent guidelines on the use of PCSK9 inhibitors for the treatment of peripheral arterial disease.
- Provider:Lippincott Continuing Medical Education Institute, Inc.
- Activity Link: https://www.audio-digest.org/Specialties/Internal-Medicine
- Start Date: 2023-01-06 06:00:00
- End Date: 2023-01-06 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 2.0 hours
- MOC Credit Details: ABIM - 2.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: No
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: Yes
- Measured Outcome: Learner Competence, Learner Knowledge, Learner Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Cardiovascular Disease, Rheumatology